Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.
Haslett, Kate Franks, K Hanna, G Harden, S Hatton, M Harrow, S McDonald, F Ashcroft, Linda Falk, S Groom, N
Haslett, Kate
Franks, K
Hanna, G
Harden, S
Hatton, M
Harrow, S
McDonald, F
Ashcroft, Linda
Falk, S
Groom, N
Citations
Altmetric:
Abstract
The majority of stage III patients with non-small cell lung cancer (NSCLC) are unsuitable for concurrent chemoradiotherapy, the non-surgical gold standard of care. As the alternative treatment options of sequential chemoradiotherapy and radiotherapy alone are associated with high local failure rates, various intensification strategies have been employed. There is evidence to suggest that altered fractionation using hyperfractionation, acceleration, dose escalation, and individualisation may be of benefit. The MAASTRO group have pioneered the concept of 'isotoxic' radiotherapy allowing for individualised dose escalation using hyperfractionated accelerated radiotherapy based on predefined normal tissue constraints. This study aims to evaluate whether delivering isotoxic radiotherapy using intensity modulated radiotherapy (IMRT) is achievable.
Description
Date
2016
Publisher
Collections
Keywords
Type
Article
Citation
Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. 2016, 6 (4):e010457 BMJ Open